Skip to main content

Clinical Trials Using Anti-OX40 Monoclonal Antibody

Review the clinical trials studying anti-ox40 monoclonal antibody on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-4 of 4

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Status: Active
Location: 11 locations
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Status: Active
Location: 7 locations
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Status: Enrolling by Invitation
Location: See ClinicalTrials.gov
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients with Advanced Malignancies
Status: Temporarily Closed to Accrual and Intervention
Location: See ClinicalTrials.gov